PATENT CLAIM ANALYSIS

Application Number: 16325626
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "256000"]

Abstract:
Provided are a phosphodiesterase-4 (PDE4) inhibitor and application thereof in preparation of a medication for treating a disease related to PDE4. Specifically disclosed is a compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.

Claim (Index 4):
The compound or the pharmaceutically acceptable salt thereof according to  claim 1 , wherein R 3  is selected from the group consisting of cyclopropyl, cyclobutyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, isoxazolyl and isothiazolyl, each of which is optionally substituted by 1, 2 or 3 R.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 99.0
- Lexical Diversity: 1.34375
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['16326976', '15314599', '16317510', '15128064', '15812142']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8136553007133621
- 35 USC 102 Novelty (BERT): 0.5470970070588365
- Combined Prediction Score: 0.7869994713479096
- Mean Citation Score: 379.939528
- Max Citation Score: 390.95236
- Similarity Product: 343.76879036127565

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test